This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

Dosing and Administration – Compatibility of XARELTO Oral Suspension with NG- or G-Tube

Last Updated: 01/10/2024

SUMMARY  

  • An in vitro compatibility study indicated that XARELTO suspension can be used with PVC, polyurethane or silicone NG tubing.1
  • XARELTO oral suspension may be given through NG or gastric feeding tube.1
  • There are no additional recommendations on the use of alternative administration methods for XARELTO suspension at this time.

PRODUCT LABELING

Administration Options

Administration of XARELTO suspension via NG tube or gastric feeding tube: XARELTO oral suspension may be given through NG or gastric feeding tube. After the administration, flush the feeding tube with water.1

An in vitro compatibility study indicated that XARELTO suspension can be used with PVC, polyurethane or silicone NG tubing.1

Additional DATA

For the investigational product preparation during the UNIVERSE clinical trial, the following materials were not provided and were the responsibility of the clinical site2:

  • Connector between the oral dosing pipette and nasogastric or gastric feeding tube (PVC, Polyurethane, Silicone, PE).
  • Nasogastric or gastric feeding tube (PVC, Polyurethane, Silicone).
  • Rinsing syringe for the nasogastric or gastric feeding tube.

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, DERWENT® (and/or other resources, including internal/external databases) was conducted on 04 January 2024.

References

1 XARELTO (rivaroxaban) Tablets [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; https://imedicalknowledge.veevavault.com/ui/approved_viewer?token=7994-2a7e16dc-2859-4486-a5a4-8838e35d61a6
2 Data on File. Investigational Product Preparation Instructions for Clinical Trial 39039039CHD3001; 2022.